Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Pharmacological Research as a Key Component in Mitigating the Opioid Overdose Crisis.

Baumann MH, Kopajtic TA, Madras BK.

Trends Pharmacol Sci. 2018 Dec;39(12):995-998. doi: 10.1016/j.tips.2018.09.006. Review.

PMID:
30454770
2.

Tinkering with THC-to-CBD ratios in Marijuana.

Madras BK.

Neuropsychopharmacology. 2019 Jan;44(1):215-216. doi: 10.1038/s41386-018-0217-3. Epub 2018 Sep 19. No abstract available.

PMID:
30232407
3.

Drug use among youth: National survey data support a common liability of all drug use.

DuPont RL, Han B, Shea CL, Madras BK.

Prev Med. 2018 Aug;113:68-73. doi: 10.1016/j.ypmed.2018.05.015. Epub 2018 May 17.

PMID:
29758306
4.

The President's Commission on Combating Drug Addiction and the Opioid Crisis: Origins and Recommendations.

Madras BK.

Clin Pharmacol Ther. 2018 Jun;103(6):943-945. doi: 10.1002/cpt.1050. Epub 2018 Mar 23.

PMID:
29570781
5.

Ineffective Policies to Address the Opioid Epidemic-Reply.

Madras BK.

JAMA Psychiatry. 2017 Sep 1;74(9):974-975. doi: 10.1001/jamapsychiatry.2017.1668. No abstract available.

PMID:
28793148
6.

The Surge of Opioid Use, Addiction, and Overdoses: Responsibility and Response of the US Health Care System.

Madras BK.

JAMA Psychiatry. 2017 May 1;74(5):441-442. doi: 10.1001/jamapsychiatry.2017.0163. No abstract available.

PMID:
28355456
7.

Are THC Levels in Oral Fluids and Blood Plasma Comparable after Oral Ingestion of Edibles Containing Cannabis or THC?

Madras BK.

Clin Chem. 2017 Mar;63(3):629-631. doi: 10.1373/clinchem.2016.269795. Epub 2017 Feb 10. No abstract available.

8.

The Growing Problem of New Psychoactive Substances (NPS).

Madras BK.

Curr Top Behav Neurosci. 2017;32:1-18. doi: 10.1007/7854_2016_34.

PMID:
27571747
9.

Cannabis and Medicinal Properties.

Madras BK.

S D Med. 2016 Spec;No:34-45. No abstract available.

PMID:
28817848
10.

Vesicular monoamine transporter 2 loss in human cocaine abusers confirmed in nonhuman primate brain.

Madras BK.

Biol Psychiatry. 2015 Mar 1;77(5):421-2. doi: 10.1016/j.biopsych.2014.12.015. No abstract available.

PMID:
25645272
11.

Dopamine challenge reveals neuroadaptive changes in marijuana abusers.

Madras BK.

Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):11915-6. doi: 10.1073/pnas.1412314111. Epub 2014 Aug 11. No abstract available.

12.

Response to Selveraj et al.

Faraone SV, Spencer TJ, Madras BK, Zhang-James Y, Biederman J.

Mol Psychiatry. 2014 Sep;19(9):964-5. doi: 10.1038/mp.2014.26. Epub 2014 Apr 1. No abstract available.

PMID:
24686137
13.

Functional effects of dopamine transporter gene genotypes on in vivo dopamine transporter functioning: a meta-analysis.

Faraone SV, Spencer TJ, Madras BK, Zhang-James Y, Biederman J.

Mol Psychiatry. 2014 Aug;19(8):880-9. doi: 10.1038/mp.2013.126. Epub 2013 Sep 24.

PMID:
24061496
14.

Prescription opioid abuse: challenges and opportunities for payers.

Katz NP, Birnbaum H, Brennan MJ, Freedman JD, Gilmore GP, Jay D, Kenna GA, Madras BK, McElhaney L, Weiss RD, White AG.

Am J Manag Care. 2013 Apr;19(4):295-302.

15.

History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia.

Madras BK.

J Hist Neurosci. 2013;22(1):62-78. doi: 10.1080/0964704X.2012.678199.

PMID:
23323533
16.

Functional genomics of attention-deficit/hyperactivity disorder (ADHD) risk alleles on dopamine transporter binding in ADHD and healthy control subjects.

Spencer TJ, Biederman J, Faraone SV, Madras BK, Bonab AA, Dougherty DD, Batchelder H, Clarke A, Fischman AJ.

Biol Psychiatry. 2013 Jul 15;74(2):84-9. doi: 10.1016/j.biopsych.2012.11.010. Epub 2012 Dec 27.

17.

Striatal dopamine transporter binding in adults with ADHD.

Spencer TJ, Madras BK, Fischman AJ, Krause J, La Fougère C.

Am J Psychiatry. 2012 Jun;169(6):665; author reply 666. doi: 10.1176/appi.ajp.2012.12020232. No abstract available.

PMID:
22684601
18.

Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.

Torun L, Madras BK, Meltzer PC.

Bioorg Med Chem. 2012 Apr 15;20(8):2762-72. doi: 10.1016/j.bmc.2012.01.053. Epub 2012 Feb 8.

19.

Growth-associated protein-43 and ephrin B3 induction in the brain of adult SIV-infected rhesus macaques.

Westmoreland SV, Annamalai L, Lentz MR, Ratai EM, Assaf B, Boisvert K, Huynh T, Vallender EJ, Miller GM, Madras BK, Gonzalez RG.

J Neurovirol. 2011 Oct;17(5):455-68. doi: 10.1007/s13365-011-0047-0. Epub 2011 Jul 26.

20.

Candidate performance measures for screening for, assessing, and treating unhealthy substance use in hospitals.

Madras BK.

Ann Intern Med. 2011 Jan 4;154(1):72-3; author reply 73-4. doi: 10.7326/0003-4819-154-1-201101040-00016. No abstract available.

PMID:
21200046
21.

The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.

Purushotham M, Sheri A, Pham-Huu DP, Madras BK, Janowsky A, Meltzer PC.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):48-51. doi: 10.1016/j.bmcl.2010.11.076. Epub 2010 Nov 21.

22.

A positron emission tomography study examining the dopaminergic activity of armodafinil in adults using [¹¹C]altropane and [¹¹C]raclopride.

Spencer TJ, Madras BK, Bonab AA, Dougherty DD, Clarke A, Mirto T, Martin J, Fischman AJ.

Biol Psychiatry. 2010 Nov 15;68(10):964-70. doi: 10.1016/j.biopsych.2010.08.026.

PMID:
21035624
23.

Office of National Drug Control Policy: a scientist in drug policy in Washington, DC.

Madras BK.

Ann N Y Acad Sci. 2010 Feb;1187:370-402. doi: 10.1111/j.1749-6632.2009.05278.x. Review.

PMID:
20201863
24.

Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later.

Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW.

Drug Alcohol Depend. 2009 Jan 1;99(1-3):280-95. doi: 10.1016/j.drugalcdep.2008.08.003. Epub 2008 Oct 16.

25.

MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor.

Verrico CD, Lynch L, Fahey MA, Fryer AK, Miller GM, Madras BK.

J Psychopharmacol. 2008 Mar;22(2):187-202. doi: 10.1177/0269881107083639. Epub 2008 Feb 28.

PMID:
18308800
26.

Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane.

Spencer TJ, Biederman J, Madras BK, Dougherty DD, Bonab AA, Livni E, Meltzer PC, Martin J, Rauch S, Fischman AJ.

Biol Psychiatry. 2007 Nov 1;62(9):1059-61. Epub 2007 May 23.

27.

Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro.

Xie Z, Westmoreland SV, Bahn ME, Chen GL, Yang H, Vallender EJ, Yao WD, Madras BK, Miller GM.

J Pharmacol Exp Ther. 2007 Apr;321(1):116-27. Epub 2007 Jan 18.

PMID:
17234900
28.

Synthesis of 8-thiabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.

Pham-Huu DP, Deschamps JR, Liu S, Madras BK, Meltzer PC.

Bioorg Med Chem. 2007 Jan 15;15(2):1067-82. Epub 2006 Oct 27.

29.

Dopamine transporter (DAT) inhibitors alleviate specific parkinsonian deficits in monkeys: association with DAT occupancy in vivo.

Madras BK, Fahey MA, Goulet M, Lin Z, Bendor J, Goodrich C, Meltzer PC, Elmaleh DR, Livni E, Bonab AA, Fischman AJ.

J Pharmacol Exp Ther. 2006 Nov;319(2):570-85. Epub 2006 Aug 2.

PMID:
16885433
30.

Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro.

Madras BK, Xie Z, Lin Z, Jassen A, Panas H, Lynch L, Johnson R, Livni E, Spencer TJ, Bonab AA, Miller GM, Fischman AJ.

J Pharmacol Exp Ther. 2006 Nov;319(2):561-9. Epub 2006 Aug 2.

PMID:
16885432
31.

Human genetics and pharmacology of neurotransmitter transporters.

Lin Z, Madras BK.

Handb Exp Pharmacol. 2006;(175):327-71. Review.

PMID:
16722243
32.

Receptor regulation of gene expression of axon guidance molecules: implications for adaptation.

Jassen AK, Yang H, Miller GM, Calder E, Madras BK.

Mol Pharmacol. 2006 Jul;70(1):71-7. Epub 2006 Apr 4.

PMID:
16595738
33.

PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate.

Spencer TJ, Biederman J, Ciccone PE, Madras BK, Dougherty DD, Bonab AA, Livni E, Parasrampuria DA, Fischman AJ.

Am J Psychiatry. 2006 Mar;163(3):387-95.

PMID:
16513858
34.
35.

Ephrin/Eph receptor expression in brain of adult nonhuman primates: implications for neuroadaptation.

Xiao D, Miller GM, Jassen A, Westmoreland SV, Pauley D, Madras BK.

Brain Res. 2006 Jan 5;1067(1):67-77. Epub 2005 Dec 20.

PMID:
16360648
36.

Cerebellar vermis involvement in cocaine-related behaviors.

Anderson CM, Maas LC, Frederick Bd, Bendor JT, Spencer TJ, Livni E, Lukas SE, Fischman AJ, Madras BK, Renshaw PF, Kaufman MJ.

Neuropsychopharmacology. 2006 Jun;31(6):1318-26.

37.

MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.

Verrico CD, Miller GM, Madras BK.

Psychopharmacology (Berl). 2007 Jan;189(4):489-503. Epub 2005 Oct 12.

PMID:
16220332
38.

Variants of the primate vesicular monoamine transporter-2.

Jassen AK, Brown JM, Panas HN, Miller GM, Xiao D, Madras BK.

Brain Res Mol Brain Res. 2005 Oct 3;139(2):251-7.

PMID:
15978697
39.

The dopamine transporter and attention-deficit/hyperactivity disorder.

Madras BK, Miller GM, Fischman AJ.

Biol Psychiatry. 2005 Jun 1;57(11):1397-409. Epub 2005 Jan 5. Review.

PMID:
15950014
40.

The neurobiology of attention-deficit/hyperactivity disorder.

Fischman AJ, Madras BK.

Biol Psychiatry. 2005 Jun 1;57(11):1374-6. No abstract available.

PMID:
15950010
41.

In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter.

Spencer TJ, Biederman J, Madras BK, Faraone SV, Dougherty DD, Bonab AA, Fischman AJ.

Biol Psychiatry. 2005 Jun 1;57(11):1293-300. Review.

PMID:
15950001
42.

Primate trace amine receptor 1 modulation by the dopamine transporter.

Miller GM, Verrico CD, Jassen A, Konar M, Yang H, Panas H, Bahn M, Johnson R, Madras BK.

J Pharmacol Exp Ther. 2005 Jun;313(3):983-94. Epub 2005 Mar 11.

PMID:
15764732
43.

Dopamine and norepinephrine transporter-dependent c-Fos production in vitro: relevance to neuroadaptation.

Yatin SM, Miller GM, Madras BK.

J Neurosci Methods. 2005 Apr 15;143(1):69-78.

PMID:
15763138
44.

Synthesis of 8-thiabicyclo[3.2.1]oct-2-enes and their binding affinity for the dopamine and serotonin transporters.

Meltzer PC, Pham-Huu DP, Madras BK.

Bioorg Med Chem Lett. 2004 Dec 20;14(24):6007-10.

PMID:
15546718
45.

Repetitive behaviors in monkeys are linked to specific striatal activation patterns.

Saka E, Goodrich C, Harlan P, Madras BK, Graybiel AM.

J Neurosci. 2004 Aug 25;24(34):7557-65.

46.

A mu-opioid receptor single nucleotide polymorphism in rhesus monkey: association with stress response and aggression.

Miller GM, Bendor J, Tiefenbacher S, Yang H, Novak MA, Madras BK.

Mol Psychiatry. 2004 Jan;9(1):99-108.

PMID:
14699447
47.

Non-amine-based dopamine transporter (reuptake) inhibitors retain properties of amine-based progenitors.

Madras BK, Fahey MA, Miller GM, De La Garza R, Goulet M, Spealman RD, Meltzer PC, George SR, O'Dowd BF, Bonab AA, Livni E, Fischman AJ.

Eur J Pharmacol. 2003 Oct 31;479(1-3):41-51.

PMID:
14612136
48.

Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes.

Meltzer PC, McPhee M, Madras BK.

Bioorg Med Chem Lett. 2003 Nov 17;13(22):4133-7.

PMID:
14592523
49.

A second-generation 99m technetium single photon emission computed tomography agent that provides in vivo images of the dopamine transporter in primate brain.

Meltzer PC, Blundell P, Zona T, Yang L, Huang H, Bonab AA, Livni E, Fischman A, Madras BK.

J Med Chem. 2003 Jul 31;46(16):3483-96.

PMID:
12877586
50.

Supplemental Content

Loading ...
Support Center